S&P 500   3,366.58 (-0.40%)
DOW   29,188.39 (-0.71%)
QQQ   234.36 (-0.12%)
AAPL   317.80 (-2.20%)
FB   217.30 (+1.46%)
MSFT   186.75 (+0.76%)
GOOGL   1,518.30 (-0.03%)
AMZN   2,158.95 (+1.13%)
CGC   22.63 (+2.26%)
NVDA   292.61 (+0.97%)
BABA   219.16 (-0.21%)
MU   57.69 (-1.38%)
GE   12.72 (-0.86%)
TSLA   850.29 (+6.28%)
AMD   57.53 (+4.01%)
T   38.23 (-0.05%)
ACB   1.63 (+3.16%)
F   8.03 (-0.86%)
NFLX   388.06 (+2.01%)
PRI   135.65 (-0.87%)
BAC   34.23 (-1.78%)
DIS   138.48 (-0.76%)
GILD   66.86 (-1.04%)
S&P 500   3,366.58 (-0.40%)
DOW   29,188.39 (-0.71%)
QQQ   234.36 (-0.12%)
AAPL   317.80 (-2.20%)
FB   217.30 (+1.46%)
MSFT   186.75 (+0.76%)
GOOGL   1,518.30 (-0.03%)
AMZN   2,158.95 (+1.13%)
CGC   22.63 (+2.26%)
NVDA   292.61 (+0.97%)
BABA   219.16 (-0.21%)
MU   57.69 (-1.38%)
GE   12.72 (-0.86%)
TSLA   850.29 (+6.28%)
AMD   57.53 (+4.01%)
T   38.23 (-0.05%)
ACB   1.63 (+3.16%)
F   8.03 (-0.86%)
NFLX   388.06 (+2.01%)
PRI   135.65 (-0.87%)
BAC   34.23 (-1.78%)
DIS   138.48 (-0.76%)
GILD   66.86 (-1.04%)
S&P 500   3,366.58 (-0.40%)
DOW   29,188.39 (-0.71%)
QQQ   234.36 (-0.12%)
AAPL   317.80 (-2.20%)
FB   217.30 (+1.46%)
MSFT   186.75 (+0.76%)
GOOGL   1,518.30 (-0.03%)
AMZN   2,158.95 (+1.13%)
CGC   22.63 (+2.26%)
NVDA   292.61 (+0.97%)
BABA   219.16 (-0.21%)
MU   57.69 (-1.38%)
GE   12.72 (-0.86%)
TSLA   850.29 (+6.28%)
AMD   57.53 (+4.01%)
T   38.23 (-0.05%)
ACB   1.63 (+3.16%)
F   8.03 (-0.86%)
NFLX   388.06 (+2.01%)
PRI   135.65 (-0.87%)
BAC   34.23 (-1.78%)
DIS   138.48 (-0.76%)
GILD   66.86 (-1.04%)
S&P 500   3,366.58 (-0.40%)
DOW   29,188.39 (-0.71%)
QQQ   234.36 (-0.12%)
AAPL   317.80 (-2.20%)
FB   217.30 (+1.46%)
MSFT   186.75 (+0.76%)
GOOGL   1,518.30 (-0.03%)
AMZN   2,158.95 (+1.13%)
CGC   22.63 (+2.26%)
NVDA   292.61 (+0.97%)
BABA   219.16 (-0.21%)
MU   57.69 (-1.38%)
GE   12.72 (-0.86%)
TSLA   850.29 (+6.28%)
AMD   57.53 (+4.01%)
T   38.23 (-0.05%)
ACB   1.63 (+3.16%)
F   8.03 (-0.86%)
NFLX   388.06 (+2.01%)
PRI   135.65 (-0.87%)
BAC   34.23 (-1.78%)
DIS   138.48 (-0.76%)
GILD   66.86 (-1.04%)
Log in

NASDAQ:LPCN - Lipocine Stock Price, Forecast & News

$0.46
+0.01 (+2.21 %)
(As of 02/18/2020 01:49 PM ET)
Today's Range
$0.45
Now: $0.46
$0.47
50-Day Range
$0.36
MA: $0.45
$0.56
52-Week Range
$0.32
Now: $0.46
$3.45
Volume133,801 shs
Average Volume620,920 shs
Market Capitalization$11.77 million
P/E RatioN/A
Dividend YieldN/A
Beta0.18
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPCN
CUSIPN/A
Phone801-994-7383

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$430,000.00
Book Value$0.44 per share

Profitability

Net Income$-11,660,000.00

Miscellaneous

Employees10
Market Cap$11.77 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive LPCN News and Ratings via Email

Sign-up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.


Lipocine (NASDAQ:LPCN) Frequently Asked Questions

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How were Lipocine's earnings last quarter?

Lipocine Inc (NASDAQ:LPCN) released its quarterly earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.04. The specialty pharmaceutical company earned $0.17 million during the quarter. View Lipocine's Earnings History.

When is Lipocine's next earnings date?

Lipocine is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Lipocine.

What price target have analysts set for LPCN?

2 brokers have issued 1 year target prices for Lipocine's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Lipocine's share price to reach $2.00 in the next year. This suggests a possible upside of 331.6% from the stock's current price. View Analyst Price Targets for Lipocine.

What is the consensus analysts' recommendation for Lipocine?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lipocine.

Has Lipocine been receiving favorable news coverage?

News articles about LPCN stock have trended neutral on Tuesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lipocine earned a coverage optimism score of 0.3 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for Lipocine.

Who are some of Lipocine's key competitors?

What other stocks do shareholders of Lipocine own?

Who are Lipocine's key executives?

Lipocine's management team includes the folowing people:
  • Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 62)
  • Mr. Morgan R. Brown, Exec. VP, CFO & Corp. Sec. (Age 51)
  • Logan Morse, VP of Sales, Marketing & Operations (Age 49)
  • Nachiappan Chidambaram, VP of Product Devel. (Age 50)
  • Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 88)

Who are Lipocine's major shareholders?

Lipocine's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (7.49%) and Mercer Global Advisors Inc. ADV (0.28%). Company insiders that own Lipocine stock include Mahesh V Patel and Morgan R Brown. View Institutional Ownership Trends for Lipocine.

Which institutional investors are selling Lipocine stock?

LPCN stock was sold by a variety of institutional investors in the last quarter, including Mercer Global Advisors Inc. ADV. Company insiders that have sold Lipocine company stock in the last year include Mahesh V Patel and Morgan R Brown. View Insider Buying and Selling for Lipocine.

Which institutional investors are buying Lipocine stock?

LPCN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Lipocine.

How do I buy shares of Lipocine?

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $0.46.

How big of a company is Lipocine?

Lipocine has a market capitalization of $11.77 million and generates $430,000.00 in revenue each year. The specialty pharmaceutical company earns $-11,660,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Lipocine employs 10 workers across the globe.View Additional Information About Lipocine.

What is Lipocine's official website?

The official website for Lipocine is http://www.lipocine.com/.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]


MarketBeat Community Rating for Lipocine (NASDAQ LPCN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  487
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe LPCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Golden Cross

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel